Isoniazid, Rifampin, Pyrazinamide, Ethambutol administered for 2 months
Re-assess the patient when this phase is completed
Continuation phase
Consists of isoniazid and rifampin administered for 4 months
May be extended up to 7 months
Reasons for extending continuation phase
Patients with both cavitary pulmonary TB on initial CXR and positive sputum culture after the 2-month intensive-phase treatment
Intensive phase did not include 2 months of pyrazinamide
Some patients with HIV co-infection
Continuation phase for HIV-uninfected patients
Shortened to 2 months for patients with negative sputum cultures and symptomatic and/or radiographic improvement in the absence of an alternative diagnosis
Daily therapy is preferred over intermittent therapy during both phases (esp. intensive phase)
Dexamethasone is added as adjunct in treatment initiation in CNS and pericardial disease (decreases risk of constrictive pericarditis & neurological complications)
Baseline liver function (bilirubin, ALP, transaminases) must be established before treatment due to risk of hepatotoxicity
Asymptomatic aminotransferase elevations resolve spontaneously over days to weeks in most patients
Drug-induced hepatitis
1. Stop all hepatotoxic drugs if bilirubin ≥3 mg/dL or transaminases >3-5 times the upper limit of normal
2. Once LFTs return to baseline (or fall to less than twice normal), hepatotoxic drugs can be restarted one at a time with careful monitoring between resumption of each agent
Treatment failure
Positive cultures after 4 months of therapy
Relapse
Recurrent tuberculosis at any time after completion of treatment with apparent cure